Recombinant Human Angiopoietin-like 3 (aa 17-220), CF

• Reactivity: Hu
• Applications: Inhibition Activity
• Format: Carrier-Free

Recombinant Human Angiopoietin-like 3 (aa 17-220), CF Summary

• Details of Functionality: Measured by its ability to inhibit lipoprotein lipase activity. Yoshida, K. et al. (2002) J. Lipid Res. 43:1770. The IC₅₀ value under conditions in which Recombinant Human Lipoprotein Lipase/LPL (Catalog # 9888-LL) and p-nitrophenyl butyrate are present in 0.1 M Sodium Phosphate, 0.15 M NaCl, 0.5% Triton^® X-100, pH 7.2, is approximately <15 µg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Angiopoietin-like Protein 3/ANGPTL3 protein
  Ser17-Pro220, with a C-terminal 6-His tag
• Accession #: Q9Y5C1
• N-terminal Sequence: Ser17
• Structure / Form: Oligomer
• Protein/Peptide Type: Recombinant Proteins
• Gene: ANGPTL3
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Inhibition Activity
• Theoretical MW: 24.6 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 35-43 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Angiopoietin-like 3 (aa 17-220), CF

• AGNPT5
• Ang-5
• angiopoietin 5
• Angiopoietin-5
• angiopoietin-like 3
• Angiopoietin-like Protein 3
• angiopoietin-related protein 3
• ANGPT5angiopoietin-5
• ANGPTL3
• FHBL2

Background

Angiopoietin-like 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins (1-3). Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain (4). Within the N-terminal region, human ANGPTL3 shares 15%-21% amino acid (aa) sequence identity with ANGPTL1, 2, 4, 5, 6, and 7, and 82% with mouse and rat ANGPTL3. ANGPTL3 is expressed in the liver from early in development through adulthood (4, 5). Full length ANGPTL3 circulates in the plasma as do the proteolytically separated N- and C-terminal segments containing the coiled coil domain and fibrinogen-like domains, respectively (6, 7). ANGPTL3 is found as 70 kDa, 50 kDa, and 32 kDa species and can form weakly-associated, noncovalent multimers in vitro (5, 6). ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing circulating triglycerides and HDL phospholipids (8, 9). This activity requires a putative heparin-binding motif which is N-terminal to the coiled coil domain (6). Proteolytic removal of the fibrinogen-like domain from the N-terminal fragment serves to activate ANGPTL3 and increase its ability to inhibit LPL in vitro and function in vivo (6). ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion or uptake (6-8). ANGPTL3 knockout mice are hypolipidemic and have elevated LPL activity (10). ANGPTL3 expression in vivo is up-regulated by LXR agonists and down-regulated by insulin, leptin, and agonists of TR beta or PPAR beta (11-14). Dysregulated ANGPTL3 expression and elevated plasma triglyceride levels are characteristic of some strains of obese and diabetic mice (7, 8, 12). ANGPTL3 does not bind Tie1 or Tie2, but its fibrinogen-like domain interacts with integrin alpha V beta 3 to induce endothelial cell adhesion, migration, and neovascularization (15). ANGPTL3, secreted by fetal liver cells, also promotes the expansion of hematopoietic stem cells (16).

1. Li, C. (2006) Curr. Opin. Lipidol. 17:152.
2. Oike, Y. et al. (2004) Int. J. Hematol. 80:21.
3. Kersten, S. (2005) Biochem. Soc. Trans. 33:1059.
4. Conklin, D. et al. (1999) Genomics 62:477.
5. Ge, H. et al. (2005) J. Lipid Res. 46:1484.
6. Ono, M. et al. (2003) J. Biol. Chem. 278:41804.
7. Koishi, R. et al. (2002) Nat. Genet. 30:151.
8. Shimizugawa, T. et al. (2002) J. Biol. Chem. 277:33742.
9. Shimamura, M. et al. (2007) Arterioscler. Thromb. Vasc. Biol. 27:366.
10. Koster, A. et al. (2005) Endocrinology 146:4943.
11. Inaba, T. et al. (2003) J. Biol. Chem. 278:21344.
12. Shimamura, M. et al. (2004) Biochem. Biophys. Res. Commun. 322:1080.
13. Fugier, C. et al. (2006) J. Biol. Chem. 281:11553.
14. Matsusue, K. et al. (2006) Mol. Cell. Endocrinol. 256:23.
15. Camenisch, G. et al. (2002) J. Biol. Chem. 277:17281.
16. Zhang, C.C. et al. (2006) Nat. Med. 12:240.

Bioinformatics

• Gene Symbol: ANGPTL3
• Uniprot:
  • Q9Y5C1(Human)